Announcement PDF Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 1 ASX ANNOUNCEMENT Actinogen secures funding beyond XanaMIA Alzheimer’s disease trial topline final results in November followingpositiveinterim analysis outcome - share placement and share purchase plan to raise up to approximately $17.0 million Highlights: • Following the release of the positive result of its XanaMIA Alzheimer’s trial Interim Analysis on Friday, Actinogen has received firm commitments for a non-underwritten share placement of approximately 285.7 million shares to raise approximately $12.0 million1 (before costs) at an issue price of $0.042 per share • CEO, Dr Steven Gourlay, subscribed for $500,000 in the placement, while other directors subscribed for $167,000 in aggregate. All Director participation in the placement is subject to shareholder approval at an Extraordinary General Meeting (EGM) to be advised • Funds raised will be used to complete the XanaMIA pivotal trial in Alzheimer’s disease, implement the open-label extension phase of the XanaMIA trial and for general corporate purposes • The Company also intends to undertake a non-underwritten share purchase plan (SPP) offer to eligible shareholders to raise up to an additional $5.0 million (before costs) with the ability to accept oversubscriptions, subject to ASX Listing Rules. Sydney, 2 February 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce it has received firm commitments for a share placement to sophisticated and professional investors and Directors to raise approximately $12.0 million (before costs) through the issue of approximately 285.7 million new fully paid ordinary shares in the Company, at an issue price of $0.042 per share. The issue of the new shares (excluding Director participation) will be under the Company’s Listing Rule 7.1 capacity. Proceeds from the placement (including Director participation, which is subject to shareholder approval for Director participation) will be used to complete the XanaMIA pivotal trial in Alzheimer’s disease, implement the open-label extension phase of the XanaMIA trial, and for general corporate purposes. Actinogen's Managing Director and CEO, Dr Steven Gourlay, commented: “We are delighted with the continued support of existing shareholders and welcome new investors to our register through the placement, including several high-quality institutional investors.” “Together with the positive interim analysis recommendation from the independent Data Monitoring Committee as announced on 30 January 2026, the placement represents a material de-risking event for ACW’s XanaMIA phase 2b/3 AD trial, which is progressing towards completion and final topline results in November 2026.” “We are pleased to offer eligible retail shareholders the opportunity to participate in a share purchase plan on the same terms as the placement, up to $30,000 per eligible shareholder.” 1 Unless stated otherwise, all financial data is in Australian dollars Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 2 Webinar today ACW management will conduct a webinar at 11am today to discuss the Company’s clinical trial program including the Interim Analysis along with details of the capital raising. Pre-register now, or join at 11am Sydney time today by clicking on the following link or pasting the address into your browser: https://investors.actinogen.com.au/webinars/7eXLqe-positive-xanamia-trial-interim-analysis-funding-secured- beyond-final-results The webinar presentation is attached to this announcement. At the conclusion of the presentation, there will be an opportunity for questions from webinar attendees. A recording of the webinar will be made available as soon as possible after the conclusion of the event on the Company’s Investor Hub using the same link above to access. Details of the placement The Company has received firm commitments fora non-underwritten placement of approximately 285.7 million new shares to new and existing sophisticated and institutional investors and Directors at an issue price of $0.042 per share to raise approximately $12.0 million. New shares issued under the placement represent approximately 9.0% of current shares on issue in the Company. The issue price under the placement represents a: • 6.7% discount to the last traded price of $0.045 per share on Wednesday, 28 January 2026; and • 13.5% discount to the 5-day volume weighted average price (“VWAP”) of $0.049 per share as at Wednesday, 28 January New shares issued under the placement will rank equally with existing shares on issue. Canaccord Genuity (Australia) Limited is acting as Lead Manager to the placement and SPP. Director participation Led by CEO and MD Dr Steven Gourlay, ACW’s Directors have committed, subject to ACW shareholder approval, to participate in the placement on the same terms for an aggregate amount of approximately $667,000. Shareholder approval under ASX Listing Rule 10.11 in respect of the Director participation will be sought by the Company at a forthcoming EGM, which is currently expected to be held in March 2026. The Company will issue a Notice of Meeting with further details of the EGM in due course. Share purchase plan (SPP) In addition to the placement, the Company intends to undertake an SPP to raise up to approximately $5.0 million. The proposed SPP will provide eligible shareholders with a registered address in Australia, New Zealand and (under limited circumstances and by invitation only) the United States as at the SPP Record Date of 7.00pm (AEDT) on 30 January 2026 with the opportunity to increase their holding by up to $30,000 of new shares at the same issue price as the placement without incurring any brokerage or transaction costs. ACW will reserve the right to increase the size of the SPP or scale back applications in its absolute discretion. The SPP is expected to open on 10 February 2026 and close at 5.00pm (AEDT) on 24 February 2026. Further information on the SPP, including details on how eligible shareholders may participate, will be provided in due course. Pro forma capital structure The table below sets out, for illustrative purposes only, the existing share capital structure of the Company (before the placement and SPP) together with the impact of the issue of the new shares under the placement and SPP. The table below does not account for the impact of any options on issue which may be exercised prior to the SPP Record Date. Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 3 Detail Number Existing shares on issue 3,191,745,696 Maximum number of new shares to be issued under the placement (assuming shareholder approval of director participation) 285,714,286 Maximum number of new shares to be issued under the SPP (approximately) 119,047,619 Maximum number of shares on issue following completion of the placement and SPP (assuming full subscription under the SPP) 3,596,507,601 Timetable Outlined below is an indicative timetable of events and dates relating to the placement and SPP. Indicative Timetable* Event Date Record date for SPP 7:00pm (AEDT), Friday, 30 January 2026 Trading halt lifted, announce completion of placement and conduct of SPP Monday, 2 February 2026 Settlement of new shares under the placement Friday, 6 February 2026 Allotment and quotation of new shares under the placement Monday, 9 February 2026 SPP offer booklet and application form made available to eligible shareholders SPP offer opens Tuesday, 10 February 2026 SPP offer closes 5:00pm (AEDT), Tuesday, 24 February 2026 Announcement of results of SPP Friday, 27 February 2026 Issue of New Shares under SPP Monday, 2 March 2026 Expected commencement of trading of SPP New Shares on ASX Tuesday, 3 March 2026 EGM to approve issue of new shares to Directors under the placement Expected to be in or around March 2026 Settlement of new shares to Directors under the placement Expected to be in or around March 2026 Allotment and trading of New Shares to Directors under the placement Expected to be in or around March 2026 *Note: The above timetable is indicative only and subject to change. Subject to the requirements of the Corporations Act 2001 (Cth), the ASX Listing Rules, the Companyreserves the rightto amend thistimetable at anytime without notice. Allreferencesto time are to Sydney time. Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 4 View this announcement on our InvestorHub: https://investors.actinogen.com.au/link/PGKKgP ENDS Investors Media Dr Steven Gourlay Michael Roberts George Hazim CEO & Managing Director Investor Relations Media & Public Affairs Australia P: +61 2 8964 7401 M: +61 423 866 231 M: +61 417 516 262 E. steven.gourlay@actinogen.com.au E. michael.roberts@actinogen.com.au E: georgehazim@mediaaffairs.com.au Announcement authorised by the Board of Actinogen Medical Limited About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol.There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health. Cognitive function means how a person understands,remembers and thinks clearly.Cognitive functions include memory, attention, reasoning, awareness and decision-making. Actinogen is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer’s Disease. It has also conducted a phase 2 trial in patients with cognitive impairmentand depression andmay study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impactin these and many other diseases.The cognitive dysfunction,behavioural abnormalities,and neuropsychological burden associated with these conditions is debilitating for patients,and there is a substantial unmetmedical need for new and improved treatments. Clinical Trials The XanaMIA Phase 2b/3 Alzheimer’s disease trial is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 220 patients with mild to moderate AD and progressive disease, determined by clinical criteria and confirmed by an elevated level of the pTau181 protein biomarker in blood.Patients receive Xanamem 10 mg or placebo, once daily,and its ability to slow progression of Alzheimer’s disease is assessed with a variety of endpoints.The primary endpointof the trial is the internationally-recognized CDR-SB (Clinical Dementia Rating scale – Sum of Boxes). The trial is being conducted in Australia and the US. On 30 January, 2026 the independent Data Monitoring Committee recommended the trial continue without amendmentfollowing an unblinded review of safety and efficacy futility data.The trial is now closed to recruitment, with final topline results in November 2026. The XanaMIA-OLE Alzheimer’s disease open-label extension is an open-label phase of up to 25 months treatment where all participants will receive active Xanamem 10 mg once daily.The trial will evaluate safety and a limited number of efficacy endpoints such as the CDR-SB. The trial will commence in Q1 2026 and be open to all former and current participants in the XanaMIA Phase 2b/3 trial. The XanaCIDD Phase 2a depression trial was a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 167 patients with moderate, treatment-resistant depression and a degree of baseline cognitive impairment. Participants were evenly randomized to receive Xanamem 10 mg once daily or placebo, in most cases in addition to their existing antidepressanttherapy,and effects on cognition and depressionwere assessed.Trial results were reported in August 2024 and showed clinically and statistically significantbenefits on depression symptoms with positive effects on the MADRS scale (a validated scale of depression symptom measurement) and the PGI-S (a valid patient reported assessmentof depression severity). Cognition improved markedly and to a similar extent in both Xanamem and placebo groups. Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 5 About Xanamem (emestedastat) Xanamem’s novel mechanism is to control elevated levels of cortisol (aka the “stress hormone”) in the brain through the inhibition of the cortisol synthesis enzyme,11β-HSD1,withoutaffecting production of cortisol by the adrenal glands which is essential for the body’s normal functioning.Xanamem is a first-in-class,once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex. To view Xanamem’s two-minute Mechanism of Action animation, click here. Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be toxic to brain cells. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials. The recent XanaCIDD trial demonstrated clinically and sometimes statistically significant benefits on depressive symptoms, further validating the cortisol control mechanism for the Xanamem 10 mg oral daily dose. The Company has studied 11β-HSD1 inhibition by Xanamem in approximately 400 volunteers and patients in eightclinical trials. Xanamem has a promising safety profile and has demonstrated clinical activity in patients with depression,patients with biomarker-positive Alzheimer’s disease and cognitively normal volunteers. High levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. Xanamem is an investigational productand is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical. Disclaimer This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates,assumptions andqualifications;and relate to circumstances and events thathave nottaken place and may nottake place.Such forward looking statements should be considered “at-risk statements” - notto be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements.You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievementor reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised. ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP. Oral Xanamem® Controlling brain cortisol to slow progression in Alzheimer’s disease and treat depression Investor Presentation 2 February 2026 ® Xanamem is a registered trademark of Actinogen Medical Limited 2 This presentation is dated 2 February 2026 and has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. It should be read in conjunction with the Company’s most recent financial report and other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (”ASX”), which are available at www.asx.com.au under the Company’s ticker code (ASX: ACW). This presentation does NOT constitute a “Prospectus” or a “Disclosure Document” (as defined in the Corporations Act 2001 (Cth)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act 2001 (Cth). This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. This presentation is not for general distribution or third party reliance or use. The distribution of this presentation in the United States and elsewhere outside Australia may be restricted by law and you should observe any such restrictions. Any recipient of this presentation who is outside Australia must observe any such restrictions. This presentation has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 (the “US Securities Act”) and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management in respect of which there is NO guarantee of future performance. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends. A number of important factors could cause the Company’s actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward looking statements, including (without limitation) the risks and uncertainties associated with the ongoing impacts of the Australian and global economic environment and capital market conditions and the risk factors described in the slides titled "Summary of key risks", with many of these factors are beyond the Company’s control. To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (Parties) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation. Disclaimer Investor Presentation 2 February 2026 3 Executive summary Capital raising to progress XanaMIA phase 2b/3 pivotal trial to completion in 2026 Actinogen’s Xanamem program • Actinogen is developing a once daily pill called Xanamem/emestedastat for Alzheimer’s disease and expects final topline results from its first pivotal clinical trial in November 2026 – depression, anxiety and other dementias may be further investigated in the future, most likely in partnership with a global biopharmaceutical company • An independent Data Monitoring Committee (DMC) confidentially reviewed unblinded safety and efficacy data in late January and recommended the trial continue without amendment • This positive result confirms the trial has cleared the pre-specified efficacy futility hurdle and maintained a promising safety profile, materially de-risking the program as it advances toward final topline results in November 2026 Company outlook • Actinogen plans to complete the XanaMIA trial this year and, with positive results in hand, immediately proceed to the next pivotal, phase 3 Alzheimer’s trial and engage with major, global strategic biopharma companies interested in Alzheimer’s disease • A smaller, regional deal may be completed during the year if the terms are favourable Capital raising • Actinogen has received firm commitments to raise approximately A$12.0 million (before costs) via a non-underwritten placement (“Placement”) and is expected to raise up to a further approximately A$5.0 million via a share purchase plan (“SPP”) • The net proceeds of the Placement and SPP will be used to complete the XanaMIA pivotal trial in Alzheimer’s disease, implement the open-label extension phase of the XanaMIA trial and for general corporate purposes • Company funded beyond topline results in November 2026 after current fundraising round Director participation • Director participation of ~A$0.667 million (including CEO Steven Gourlay $0.5m) in the Placement is subject to shareholder approval at an Extraordinary General Meeting (“EGM”) to be held in or around March 2026 Investor Presentation 2 February 2026 3 Interim analysis positive trial recommendation Assessments of safety and “efficacy futility” Recommendation: • Continue the XanaMIA trial without amendment to its final conclusion for the 247 participants Methods: • Independent Data Monitoring Committee (DMC) chaired by Alzheimer’s disease trials expert Dr Hans Moebius • Data confidentially reviewed included “unblinded” data on: ✓ Safety (n=247, i.e. all enrolled participants) ✓ Efficacy data from approximately 37% of total, expected trial dataset (code broken to see treatment group assignment) from Week 12 (n=136), Week 24 (n=87) and Week 36 data (n=52) Positive result confirms the trial cleared the pre-specified efficacy futility hurdle and unblinded safety review, materially de-risking the program as it advances toward final topline results in November Investor Presentation 2 February 2026 4 5 Management Team Highly experienced Board and management with strong track record Board of Directors Dr. Geoff Brooke Chairman MBBS; MBA Dr. Steven Gourlay CEO & MD MBBS; FRACP; PhD; MBA Mr. Malcolm McComas Non-Executive Director BEc, LLB; FAICD; SF Fin Dr. George Morstyn Non-Executive Director MBBS; PhD; FRACP CD Dr. Nicki Vasquez Non-Executive Director PhD Dr. Dana Hilt Chief Medical Officer MD Dr. Steven Gourlay CEO & MD Will Souter Chief Financial Officer BComm, LLB Andrew Udell Chief Commercial Officer MBA Cheryl Townsend VP Clinical Operations RN, M Health Law Fujun Li Head of Manufacturing PhD Michael Roberts Head of IR & Comms B.Ec (Hons), CPA, FFIN Investor Presentation 2 February 2026 5 Alzheimer’s disease market is large and growing Growing Alzheimer’s Disease market – U.S. Large, unsatisfied and growing market Sources: U.S. burden of Alzheimer’s disease, related dementias to double by 2060 | CDC Online Newsroom | CDC, US Alzheimer’s Prevalence Surpasses 7 Million and The Cost of Dementia in 2025 - April 23, 2025 - USC Schaeffer Investor Presentation 2 February 2026 6 Xanamem’s unique mechanism of action Click here for animation video Investor Presentation 2 February 2026 7 Xanamem has a clear path to Alzheimer’s approval Phase 2b/3 trial on track, FDA agreement streamlines development, EMA meeting 2026 • Recent FDA agreement confirms development pathway to US marketing approval using one additional pivotal trial of 10 mg vs. placebo and open-label safety studies • Clear guidance on manufacturing, ancillary studies • Ongoing XanaMIA pivotal clinical trial: ✓ Full enrolment in US and Australia ✓ Excellent safety profile, positive first Data Monitoring Committee (DMC) safety review ✓ Positive second DMC review with unblinded interim analysis result confirms the trial cleared the pre-specified efficacy futility hurdle and unblinded safety review ✓ On-track for final results in November 2026 • Phase 3 planning commencing in parallel with discussions re potential partnerships Investor Presentation 2 February 2026 8 Highlights of Alzheimer’s treatment landscape Oral Xanamem is leading the charge with a potential game-changing new mechanism Mechanistic Admin Comments Older drugs - boosting acetylcholine or glutamate Oral • Marketed since '90s/'00s, symptomatic only. Gastrointestinal side effects. Anti-amyloid protein immunotherapies IV/SubQ • Marketed with challenges including variable reimbursement (e.g. not Aust.). Safety concerns including infusion reactions, brain swelling / bleeding - MRI monitoring required Second-gen anti-amyloid with “bra